Evaluation of disease patterns, treatment and prognosis of tuberculosis in AIDS patient

Evaluation of disease patterns, treatment and prognosis of tuberculosis in AIDS patient

Patterns of disease, diagnosis, treatment and prognosis of tuberculosis in 100 patients co-infected with AIDS at Casa da AIDS clinic was studied. Demographic characteristics were as follows: 76 male patients, 24 female patients, 67 caucasian, average 35.8 years-old (SD ± 8.5). Sexual transmission of...

Full description

Bibliographic Details
Main Authors:	Angela Naomi Atomiya, David Emerson Uip, Olavo Henrique Munhoz Leite
Format:	Article
Language:	English
Published:	Elsevier
Series:	Brazilian Journal of Infectious Diseases
Subjects:	AIDS tuberculosis rifampin isoniazid pyrazinamide
Online Access:	http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702002000100005&lng=en&tlng=en

Similar Items

Evaluation of disease patterns, treatment and prognosis of tuberculosis in AIDS patient
by: Atomiya Angela Naomi, et al.
Published: (2002-01-01)

The molecular basis of resistance to isoniazid, rifampin, and pyrazinamide in <it>Mycobacterium tuberculosis</it>
by: Parsons Linda M, et al.
Published: (2001-04-01)

CNS tuberculoma in an immunocompetent patient: A case report of multi-drug hypersensitivity to RIPE therapy
by: Benjamin Huber, et al.
Published: (2023-01-01)

Assessment of adherence to antituberculosis drug regimen among patients receiving isoniazid, rifampin and pyrazinamide: Kerman, Iran
by: Seyyed Mojtaba Sohrevardi, et al.
Published: (2019-07-01)

New combination for patients with latent tuberculosis infection: A pilot study
by: Te-Yu Lin, et al.
Published: (2018-01-01)

Is the Pharmacokinetics of First-Line Anti-TB Drugs a Cause of High Mortality Rates in TB Patients Admitted to the ICU? A Non-Compartmental Pharmacokinetic Analysis
by: Francisco Beraldi-Magalhaes, et al.
Published: (2023-06-01)

Intestinal barrier function and serum concentrations of rifampin, isoniazid and pyrazinamide in patients with pulmonary tuberculosis
by: Mônica C. Façanha, et al.

A comparative study on the adverse effects of two anti-tuberculosis drugs regimen in initial two-month treatment period
by: Begum Lutfun Nahar, A.K.M. Mosharrof Hossain, M. Monirul Islam and Dipti Rani Saha
Published: (2006-12-01)

Mutations in rpoB and katG genes in Mycobacterium isolates from the Southeast of Mexico
by: R Zenteno-Cuevas, et al.
Published: (2009-05-01)

Pharmacokinetics of antitubercular drugs in patients hospitalized with HIV-associated tuberculosis: a population modeling analysis [version 3; peer review: 1 approved, 2 approved with reservations]
by: Helen McIlleron, et al.
Published: (2024-03-01)

Pharmacokinetics of antitubercular drugs in patients hospitalized with HIV-associated tuberculosis: a population modeling analysis [version 2; peer review: 1 approved, 2 approved with reservations]
by: Helen McIlleron, et al.
Published: (2022-11-01)

Drug Resistance in Mycobacterium Tuberculosis Isolates to Isoniazid and Rifampin
by: M Pourhajibagher, et al.
Published: (2012-05-01)

Evidenziazione molecolare di resistenza di Mycobacterium tuberculosis complex a rifampicina e isoniazide
by: Gian Lorenzo Molinari, et al.
Published: (2006-06-01)

Correlations among the plasma concentrations of first-line anti-tuberculosis drugs and the physiological parameters influencing concentrations
by: Lin Cheng, et al.
Published: (2023-10-01)

Evaluation of the frequency of resistance to 2 drugs (Isoniazid and Rifampin) by molecular investigation and it's risk factors in new cases of smear positive pulmonary tuberculosis in health centers under the cover of Jundishapur University of Medical Sciences in 2017
by: Shokrollah Salmanzadeh, et al.
Published: (2020-01-01)

Tuberculose resistente: revisão molecular
by: Maria Lúcia Rosa Rossetti, et al.

The Prospective Synergy of Antitubercular Drugs With NAD Biosynthesis Inhibitors
by: Kyle H. Rohde, et al.
Published: (2021-01-01)

Mutations and insights into the molecular mechanisms of resistance of Mycobacterium tuberculosis to first-line
by: Nicolas de Oliveira Rossini, et al.
Published: (2023-01-01)

Multidrug-resistant Mycobacterium tuberculosis in HIV-Infected Persons, Peru
by: Pablo E. Campos, et al.
Published: (2003-12-01)

Therapeutic Drug Monitoring for Slow Response to Tuberculosis Treatment in a State Control Program, Virginia, USA
by: Scott K. Heysell, et al.
Published: (2010-10-01)

Effect of Carum carvi, a herbal bioenhancer on pharmacokinetics of antitubercular drugs: A study in healthy human volunteers
by: Naiyma Choudhary, et al.
Published: (2014-01-01)

Intestinal permeability and malabsorption of rifampin and isoniazid in active pulmonary tuberculosis
by: Valéria G. F. Pinheiro, et al.

Antibiotic heteroresistance in Mycobacterium tuberculosis isolates: a systematic review and meta-analysis
by: Mao Ye, et al.
Published: (2021-10-01)

SIMULTANEOUS CONTENT ANALYSIS OF RIFAMPICIN, ISONIAZID, AND PYRAZINAMIDE IN TABLET DOSAGE FORM BY SPECTROPHOTOMETRY ULTRAVIOLET WITH DWM AND RSM
by: Muhammad Andry, et al.
Published: (2022-11-01)

Comparative analysis of the effectiveness of tuberculosis prophylaxis in patients with HIV/AIDS treated with isoniazid
by: Konrad Juszkiewicz, et al.
Published: (2019-09-01)

Adverse Drug Reactions to a Daily Fixed-dose Combination Based Antituberculosis Treatment Regime in India’s National Tuberculosis Elimination Programme: A Prospective Cohort Study
by: Kapil Mate, et al.
Published: (2022-08-01)

Development of a HPLC Method for Analysis of a Combination of Clofazimine, Isoniazid, Pyrazinamide, and Rifampicin Incorporated into a Dermal Self-Double-Emulsifying Drug Delivery System
by: Daniélle van Staden, et al.
Published: (2023-11-01)

Simultaneous detection and differentiation of Mycobacterium tuberculosis and nontuberculous mycobacteria coexisting in patients with pulmonary tuberculosis by single-tube multiplex PCR
by: Leila Heidari, et al.
Published: (2023-06-01)

Contributions to the diagnosis of pirazinamide resistance in Mycobacterium tuberculosis
by: Ernesto Montoro, et al.
Published: (2011-12-01)

Prevalencia de la resistencia de Mycobacterium tuberculosis a quinolonas y fármacos inyectables en Colombia, 2012-2013
by: Claudia Llerena, et al.
Published: (2017-01-01)

Retrospective Analysis of Archived Pyrazinamide Resistant <i>Mycobacterium tuberculosis</i> Complex Isolates from Uganda—Evidence of Interspecies Transmission
by: Sylvia I. Wanzala, et al.
Published: (2019-07-01)

Hepatoprotective activity of the ethanol extract of Curcuma heyneana rhizome on isoniazid and rifampin-induced liver injury rats
by: Marianne Marianne, et al.
Published: (2020-10-01)

A model-based approach for a practical dosing strategy for the short, intensive treatment regimen for paediatric tuberculous meningitis
by: Roeland E. Wasmann, et al.
Published: (2023-04-01)

Molecular detection of rifampin, isoniazid, and ofloxacin resistance in Iranian isolates of Mycobacterium tuberculosis by high-resolution melting analysis
by: Sirous M, et al.
Published: (2018-10-01)

Development and Validation of a UPLC-MS/MS Method for Therapeutic Drug Monitoring, Pharmacokinetic and Stability Studies of First-Line Antituberculosis Drugs in Urine
by: Mohamed Abouzid, et al.
Published: (2024-01-01)

Outcome of BCG Vaccination in ADA-SCID Patients: A 12-Patient Series
by: Daniele Canarutto, et al.
Published: (2023-06-01)

Drug-Resistant Tuberculosis 2020: Where We Stand
by: Angelo Iacobino, et al.
Published: (2020-03-01)

An Evaluation of the In Vitro Roles and Mechanisms of Silibinin in Reducing Pyrazinamide- and Isoniazid-Induced Hepatocellular Damage
by: Zhang-He Goh, et al.
Published: (2020-05-01)

Stability Study of Isoniazid and Rifampicin Oral Solutions Using Hydroxypropyl-Β-Cyclodextrin to Treat Tuberculosis in Paediatrics
by: Ana Santoveña-Estévez, et al.
Published: (2020-02-01)

A Simple and Sensitive UPLC–UV Method for Simultaneous Determination of Isoniazid, Pyrazinamide, and Rifampicin in Human Plasma and Its Application in Therapeutic Drug Monitoring
by: Zhimei Jiang, et al.
Published: (2022-04-01)